Eli Lilly and Company

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: LLY Category:

Description

Eli Lilly and Company delivered a positive result and managed an all-around beat in the last quarter. The company reported a notable 37% increase in revenue compared to the same period in 2022. Excluding revenue generated from the olanzapine portfolio and COVID-19 antibodies, there was still a substantial 24% growth in Q3. This acceleration in quarter-over-quarter revenue was attributed to the success of Mounjaro, coupled with the sustained strong performances of Verzenio and Jardiance. Marketing, selling, and administrative expenses increased by 12%, driven by the costs associated with new product launches, additional indications, and compensation and benefit expenses. Research and development expenses saw a 34% increase, primarily due to higher development expenses for late-stage assets and increased investments in early-stage research. Despite challenges, the company showcased strong growth in various regions. The company’s key products showcased impressive performance, such as Verzenio with a 68% sales growth, Jardiance with a 22% revenue increase, and Mounjaro reaching over $1.4 billion in global revenue. The company provided updates on Mounjaro’s expansion efforts, emphasizing increased access for patients with type 2 diabetes in the US and progress in manufacturing expansion to meet high demand. Additionally, the company acquired POINT Biopharma Global to expand oncology capabilities into next-generation radioligand therapies.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!